Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL0175 vs Fulvestrant in postmenopausal women
NCT07366632Phase 1Not yet recruiting
- Sponsor
- Shanghai Best-Link Bioscience
- Start
- Jan 2026
- Primary completion
- May 2026
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, randomised trial of BL0175 (2 arms), sponsored by Shanghai Best-Link Bioscience. Primary endpoint: Adverse Events at 57 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
BL0175
Beyond the preview
Go deeper on NCT07366632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366632.